A Timely Conversation on Health Data Privacy | Life Sciences Snapshot Q4 2026
18 minute read | October.26.2026
US life sciences venture funding has sustained a strong trajectory in Q3 2026, continuing the momentum that has defined the year, with both deal value and deal count tracking well ahead of those of prior quarters. Funding activity has accelerated sharply since the last snapshot: Both YTD deal count and capital deployed have roughly doubled.
Read Orrick’s Q4 2026 Life Sciences Snapshot for insights on these trends, and what this means for founders looking to access capital. This issue includes a timely roundtable discussion on health data privacy, focused on misconceptions around HIPAA, the Health Insurance Portability and Accountability Act.
Contact Us
Thora Johnson
Partner
[email protected]
Samir Bakhru
Partner
[email protected]
Angus McQuilken
Business Development Associate Director
[email protected]